Update on cardiac stem cell therapy in heart failure

Area of Science:

• Regenerative Medicine
• Cardiology
• Cellular Therapy

Background:

• Ischaemic heart failure remains a leading cause of mortality worldwide.
• Current treatments offer limited efficacy in restoring cardiac function.
• Cardiac stem cell therapy presents a promising regenerative approach.

Purpose of the Study:

• To review the current status of cardiac stem cell therapy for ischaemic heart failure.
• To highlight recent clinical findings and ongoing trials.
• To discuss necessary procedural adjustments for future applications.

Main Methods:

• Review of phase I and II clinical trials evaluating stem cell therapy in ischaemic heart failure.
• Analysis of safety, feasibility, and functional outcomes.
• Discussion of ongoing phase III multicentre trials and future research directions.

Main Results:

• Phase I and II trials demonstrate the safety and feasibility of cardiac stem cell therapy.
• Moderate functional benefits have been observed in initial studies.
• Conclusive efficacy assessment awaits completion of large-scale phase III trials.
• Optimal cell type, delivery time-point, and patient selection remain areas for investigation.

Conclusions:

• Cardiac stem cell therapy for ischaemic heart failure requires distinct evaluation from acute myocardial infarction settings.
• Further optimization of cell product, including cell type, processing, and delivery parameters, is essential.
• Large-scale clinical trials are critical for definitive evaluation and regulatory approval.